Isarna Therapeutics GmbH (Isarna)

Oncology Corporate Profile

HQ Location

Leopoldstrasse 254-256
Munich, Germany 80807

Company Description

Isarna Therapeutics has an unmatched commitment to developing TGF-inhibitors that stimulate the human immune system to effectively fight cancer. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Website: http://www.isarna-therapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
trabedersen / AP 12009antisense oligonucleotideGliomaIII
trabedersen / AP 12009antisense oligonucleotideColorectal cancerI
trabedersen / AP 12009antisense oligonucleotideMelanomaI
trabedersen / AP 12009antisense oligonucleotidePancreatic cancerI
AP 11014antisense oligonucleotideVarious cancer typesPreclinical
AP 11014antisense oligonucleotideVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.isarna-therapeutics.com

Recent News Headlines

Lung Cancer Surgery Left Her 'Leaking' And Near Death. Belly Fat Saved Her Life

6/24/2016 12:03 pm

(STAT) June 24, 2016 - Jensen Leogrande is a medical trailblazer: on Friday, researchers announced that the lung cancer patient is the first patient to have a certain kind of fistula patched up with stem cells from her belly fat.

'Single Most Important' Moment for NanoString Sends Stock Soaring

5/18/2015 12:00 pm

(Puget Sound Business Journal/Health Care Inc. NW blog) May 15, 2015 - This week, a Medicare contractor recommended that the agency provide coverage of ProSigna, NanoString's breast cancer diagnostic tool and one of its main products.

Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer

10/20/2014 06:03 am

(Yahoo! Finance) Oct 20, 2014 - Taiho Oncology, Inc. announced that the FDA granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC), and that the Company has initiated a rolling NDA submission to the FDA.

HIV Patients With Cancer Pose Tx Challenge

9/13/2013 11:02 am

(MedPage Today) Sep 12, 2013 - HIV patients with cancer should avoid antiretroviral therapy based on protease inhibitors (PIs) if possible, a researcher said here.

Isis Strikes Cancer Targets Agreement Worth $31 Million With AstraZeneca

12/11/2012 10:03 am

(Fox Business/Dow Jones Newswires) Dec 11, 2012 - Isis Pharmaceuticals Inc. has struck a deal with AstraZeneca PLC to develop novel generation antisense therapeutics against five cancer targets that includes a license to develop ISIS-STAT3, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

9/13/2011 12:00 pm

(iStockAnalyst) Sept 13, 2011 - Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.